Shots:
Shionogi announced a planned acquisition of IntraBio for $2.0B, adding AQNEURSA (levacetylleucine) and IntraBio’s rare disease capabilities to its portfolio; the transaction is expected to close between November and December 2026, subject to customary conditions and regulatory approvals
AQNEURSA is approved in the US and EU for neurological manifestations of Niemann-Pick disease Type C…
Shots:
GE HealthCare entered into a definitive agreement to acquire SOFIE Biosciences from Trilantic North America for $945M in cash, with the transaction expected to close in 1H’27, subject to regulatory approvals and other closing conditions. If completed, SOFIE will become part of GE HealthCare’s PDx segment
The acquisition will establish GE HealthCare’s footprint in the…
Shots:
BioMarin has entered into a definitive agreement to acquire Alesta Therapeutics, incl. its P-I/II asset ALE1, an oral small molecule for the treatment of hypophosphatasia
As per the deal, BioMarin will acquire Alesta, with Alesta shareholders receiving $275M upfront & ~$215M in development & regulatory milestone payments
Before closing, Alesta will spin out all non-ALE1…
Shots:
Alfasigma has entered into an agreement with SEVER Life Sciences to acquire 100% of Nordic Pharma & its subsidiaries, adding the Nordimet methotrexate franchise to Alfasigma’s rheumatology portfolio alongside Jyseleca
Deal will expand Alfasigma’s commercial footprint through Nordic Pharma’s direct operations across 18 EU countries, while adding platforms in Canada & Japan. The portfolio…
Shots:
Teledyne Technologies agreed to acquire Varex Imaging for $18.90 per share in cash, valuing the transaction at approximately $1.1B, incl. Varex’s equity awards & net debt
Varex develops X-ray tubes, flat-panel & photon-counting detectors, high-voltage interconnects & imaging software used across medical imaging, oncology, industrial inspection, security & vehicle inspection
The acquisition is expected…
Shots:
Jazz Pharmaceuticals has entered into a definitive agreement to acquire Actio Biosciences, incl. its asset ABS-1230 for the treatment of KCNT1+ epilepsy; closing expected by Q4’26
Under the merger, Actio shareholders will receive $820M upfront & ~$500M in approval and sales milestones. Actio will spin out a new private company, excl. ABS-1230, which remains…
Shots:
Tarsus Pharmaceuticals has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, incl. its lead asset gildeuretinol (ALK-001), expanding Tarsus’ presence in retina care
As per the deal, Alkeus will receive ~$450M upfront ($270M cash + $180M in Tarsus stock priced at $61.38/share), plus ~$350M in regulatory & commercial milestones, & low single-digit tiered descending…
Shots:
Lantheus to merge with a wholly-owned subsidiary of Curium US, combining Curium’s global theranostics platform with Lantheus’ US radiodiagnostics business; closing expected in H1’27
As per the deal, Curium will acquire Lantheus for $102.5/share in cash, with shareholders eligible for ~$12/share in non-transferable CVRs, representing total consideration of up to $114.50/share & a transaction…
Shots:
argenx has entered into a definitive agreement to acquire Forte Biosciences, strengthening argenx’s innovative immunology portfolio with FB102
As per the deal, argenx will acquire Forte Biosciences for $77/share in cash, representing a total equity value of ~$2.2B; closing is expected in Q3’26
FB102 is an anti-CD122 antibody showing clinical PoC in vitiligo & celiac disease, with…
Shots:
Dassault Systèmes has entered into a definitive agreement to acquire ArisGlobal, creating the industry’s first unified intelligence platform
As per the deal, Dassault will acquire ArisGlobal for ~$1.8B at closing in cash & ~$200M in additional payments linked to multi-year AI-related revenue milestones; closing is expected in H2’26
Acquisition will advance Dassault Systèmes’ ambition to…

